Yahoo Web Search

Search results

1. • AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program

     FierceBiotech· 5 days ago

     AltruBio has roared back after another pivot in its twisty history, securing up to $225 million in series B funding to take an immune checkpoint enhancer through a midphase ulcerative colitis ...

2. • Robeco Institutional Asset Management B.V. Sells 180,219 Shares of Biogen Inc. (NASDAQ:BIIB)

     ETF DAILY NEWS· 1 day ago

     Robeco Institutional Asset Management B.V. trimmed its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 52.7% in the 4th quarter, according to its most recent 13F filing with the Securities ...

3. • UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...

     KTLA-TV Los Angeles· 3 days ago

     UCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...

4. • Biogen Inc. (NASDAQ:BIIB) Shares Sold by Dai ichi Life Insurance Company Ltd

     ETF DAILY NEWS· 2 days ago

     Dai ichi Life Insurance Company Ltd lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 47.1% during the fourth quarter, according to its most recent disclosure with ...

5. • AbbVie (NYSE:ABBV) Shares Down 0.1%

     ETF DAILY NEWS· 1 day ago

     AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price dropped 0.1% during mid-day trading on Thursday . The stock traded as low as $157.76 and last traded at $159.38. Approximately 903,885 ...

6. • Swiss National Bank Cuts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

     ETF DAILY NEWS· 1 day ago

     Swiss National Bank trimmed its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 9.8% in the 4th quarter, according to the company in its most recent Form ...

7. • Biogen Inc. (NASDAQ:BIIB) Shares Sold by PNC Financial Services Group Inc.

     ETF DAILY NEWS· 2 days ago

     PNC Financial Services Group Inc. reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.0% during the 4th quarter, according to the company in its most recent filing with the SEC ...

8. • Needham & Company LLC Reiterates “Buy” Rating for Biogen (NASDAQ:BIIB)

     ETF DAILY NEWS· 2 days ago

     Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “buy” rating restated by Needham & Company LLC in a report issued on Wednesday, Benzinga reports. Needham & Company LLC’s price objective ...